Netherton Syndrome

 

Below is a list of our Netherton syndrome studies that are currently enrolling.

A MULTICENTER, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, PARALLEL COMPARISON, PROOF-OF-CONCEPT STUDY OF QRX003 LOTION IN SUBJECTS WITH NETHERTON SYNDROME

• Population: Patients aged eighteen years or older
• Study Condition: Netherton Syndrome
• Study Design: The purpose of this study is to assess the dose dependent safety, tolerability and potential efficacy of QRX003 lotion in subjects with Netherton Syndrome (NS). This is a multi-center, randomized, vehicle-controlled, double-blind, parallel group comparison study of QRX003 lotion in adult subjects 18 years of age or older with NS. Approximately 18 subjects will be enrolled at approximately 7 sites. Subjects will be randomized (1:1:1) to treatment as follows:
  • 1. QRX003 (dipalmitoyl hydroxyproline) lotion, 2% (Low dose)
  • 2. QRX003 (dipalmitoyl hydroxyproline) lotion, 4% (High dose)
  • 3. Vehicle lotion

  Subjects will apply the assigned test article once daily in the morning to a designated Treatment Area for 12 weeks. Subjects will attend 5 clinic visits for up to 20 weeks.

• Compensation will be provided

 

Please contact Dr. Carolina Porter for more information regarding ongoing Netherton syndrome studies. 

 

Email: portecar@musc.edu

Phone: (843) 876-0110